Old Web
English
Sign In
Acemap
>
Paper
>
P10.04 A Budget Impact Analysis for Treatment with Ramucirumab Plus Erlotinib in Metastatic EGFR-Mutated NSCLC in the US
P10.04 A Budget Impact Analysis for Treatment with Ramucirumab Plus Erlotinib in Metastatic EGFR-Mutated NSCLC in the US
2021
J. Nilsson
Katherine B. Winfree
C. Molife
D. Bhattacharyya
Y. DYachova
X Wang
M Malmenäs
K. Taipale
Keywords:
Oncology
Internal medicine
Erlotinib
Ramucirumab
Medicine
budget impact
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]